Efficacy and safety of avastin adjuvant regular chemotherapy for non-small cell lung cancer

Abstract

Objective To investigate the efficacy and safety of avastin adjuvant regular chemotherapy for non-small cell lung cancer. Methods Forty-eight cases of non-small cell lung cancer were divided into two groups, the 24 cases in control group were treated with regular chemotherapy, and the 24 cases in observation group were treated with regular chemotherapy combined with avastin. The efficacy and safety were observed between the two groups. Results Total curative effect: those the total effective rate and CR rate in the control group were 58.33% and 12.50%, and in the observation group were 79.17%, 25.00%, the differences were significant (P<0.05). Quality of life: the increase rate and total efficiency in the control group were 12.50% and 37.50%, and those in the observation group were 37.50% and 66.67%, the differences were also significant (P<0.05). The incidence of leukopenia, bone marrow suppression, nausea or vomiting, thrombocytopenia, heparin dysfunction incidence in the control group were respectively 45.83%, 29.17%, 66.67%, 37.50%, 41.67%; the corresponding complication rates in the observation group were 29.17%, 16.67%, 45.83%, 20.83%, 20.83%, the differences were significant (P<0.05). Before and after treatment, the CD3 + , CD4 + , CD8 + , CD4 + / CD8 + in the two groups were significantly different (P<0.05); After treatment, there was significant difference between the two groups (P<0.05). Conclusions Avastin adjuvant regular chemotherapy for non-small cell lung cancer is effective, it can improve the quality of life and reduce the incidence of complications. Key words: Avastin; Chemotherapy; Non-small cell lung cancer; Clinical results